Rare cancers in the Netherlands: A population-based study

Jan M. Van Der Zwan* (Corresponding Author), Boukje A.C. Van Dijk, Otto Visser, Han J.H.J.M. Van Krieken, Riccardo Capocaccia, Sabine Siesling

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
1 Downloads (Pure)

Abstract

The conventional definition for rare disease is based on prevalence. Because of differences in prognosis, a definition on the basis of incidence was deemed to be more appropriate for rare cancers. Within the European RARECARE project, a definition was introduced that defines cancers as rare when the crude incidence rate is less than six per 100 000 per year. In this study, we applied the RARECARE definition for rare cancer to the Netherlands; this to identify the usefulness of the definition in a single country and to provide more insight into the burden of rare cancers in the Netherlands. Data for 2004 through 2008 were extracted from the Netherlands Cancer Registry and classified according to the RARECARE entities (tumour groupings). Crude and European standardized incidence rates were calculated. Out of the 260 entities, 223 (86%) were rare according to the definition, accounting for 14 000 cancers (17% of all). Considerable fluctuations in crude rates over years were observed for the major group of cancers. Rare tumours in the Netherlands constituted 17% of all newly diagnosed tumours, but were divided over 223 different entities, indicating the challenge that faces clinicians. To make the definition of rare cancers better applicable, it should be refined by taking into consideration the sex-specific incidence for sex-specific cancer sites. Moreover, a mean incidence over 5 years will provide more solid insight into the burden, eliminating large fluctuations in time of most of the cancers.

Original languageEnglish
Pages (from-to)384-390
Number of pages7
JournalEuropean journal of cancer prevention
Volume27
Issue number4
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Netherlands
Population
Neoplasms
Incidence
Rare Diseases
Registries

Keywords

  • epidemiology
  • incidence
  • rare cancers
  • the Netherlands

Cite this

Van Der Zwan, J. M., Van Dijk, B. A. C., Visser, O., Van Krieken, H. J. H. J. M., Capocaccia, R., & Siesling, S. (2018). Rare cancers in the Netherlands: A population-based study. European journal of cancer prevention, 27(4), 384-390. https://doi.org/10.1097/CEJ.0000000000000166
Van Der Zwan, Jan M. ; Van Dijk, Boukje A.C. ; Visser, Otto ; Van Krieken, Han J.H.J.M. ; Capocaccia, Riccardo ; Siesling, Sabine. / Rare cancers in the Netherlands : A population-based study. In: European journal of cancer prevention. 2018 ; Vol. 27, No. 4. pp. 384-390.
@article{98570e4d4a7e493786539dbd874fb4ea,
title = "Rare cancers in the Netherlands: A population-based study",
abstract = "The conventional definition for rare disease is based on prevalence. Because of differences in prognosis, a definition on the basis of incidence was deemed to be more appropriate for rare cancers. Within the European RARECARE project, a definition was introduced that defines cancers as rare when the crude incidence rate is less than six per 100 000 per year. In this study, we applied the RARECARE definition for rare cancer to the Netherlands; this to identify the usefulness of the definition in a single country and to provide more insight into the burden of rare cancers in the Netherlands. Data for 2004 through 2008 were extracted from the Netherlands Cancer Registry and classified according to the RARECARE entities (tumour groupings). Crude and European standardized incidence rates were calculated. Out of the 260 entities, 223 (86{\%}) were rare according to the definition, accounting for 14 000 cancers (17{\%} of all). Considerable fluctuations in crude rates over years were observed for the major group of cancers. Rare tumours in the Netherlands constituted 17{\%} of all newly diagnosed tumours, but were divided over 223 different entities, indicating the challenge that faces clinicians. To make the definition of rare cancers better applicable, it should be refined by taking into consideration the sex-specific incidence for sex-specific cancer sites. Moreover, a mean incidence over 5 years will provide more solid insight into the burden, eliminating large fluctuations in time of most of the cancers.",
keywords = "epidemiology, incidence, rare cancers, the Netherlands",
author = "{Van Der Zwan}, {Jan M.} and {Van Dijk}, {Boukje A.C.} and Otto Visser and {Van Krieken}, {Han J.H.J.M.} and Riccardo Capocaccia and Sabine Siesling",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/CEJ.0000000000000166",
language = "English",
volume = "27",
pages = "384--390",
journal = "European journal of cancer prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Van Der Zwan, JM, Van Dijk, BAC, Visser, O, Van Krieken, HJHJM, Capocaccia, R & Siesling, S 2018, 'Rare cancers in the Netherlands: A population-based study', European journal of cancer prevention, vol. 27, no. 4, pp. 384-390. https://doi.org/10.1097/CEJ.0000000000000166

Rare cancers in the Netherlands : A population-based study. / Van Der Zwan, Jan M. (Corresponding Author); Van Dijk, Boukje A.C.; Visser, Otto; Van Krieken, Han J.H.J.M.; Capocaccia, Riccardo; Siesling, Sabine.

In: European journal of cancer prevention, Vol. 27, No. 4, 01.01.2018, p. 384-390.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Rare cancers in the Netherlands

T2 - A population-based study

AU - Van Der Zwan, Jan M.

AU - Van Dijk, Boukje A.C.

AU - Visser, Otto

AU - Van Krieken, Han J.H.J.M.

AU - Capocaccia, Riccardo

AU - Siesling, Sabine

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The conventional definition for rare disease is based on prevalence. Because of differences in prognosis, a definition on the basis of incidence was deemed to be more appropriate for rare cancers. Within the European RARECARE project, a definition was introduced that defines cancers as rare when the crude incidence rate is less than six per 100 000 per year. In this study, we applied the RARECARE definition for rare cancer to the Netherlands; this to identify the usefulness of the definition in a single country and to provide more insight into the burden of rare cancers in the Netherlands. Data for 2004 through 2008 were extracted from the Netherlands Cancer Registry and classified according to the RARECARE entities (tumour groupings). Crude and European standardized incidence rates were calculated. Out of the 260 entities, 223 (86%) were rare according to the definition, accounting for 14 000 cancers (17% of all). Considerable fluctuations in crude rates over years were observed for the major group of cancers. Rare tumours in the Netherlands constituted 17% of all newly diagnosed tumours, but were divided over 223 different entities, indicating the challenge that faces clinicians. To make the definition of rare cancers better applicable, it should be refined by taking into consideration the sex-specific incidence for sex-specific cancer sites. Moreover, a mean incidence over 5 years will provide more solid insight into the burden, eliminating large fluctuations in time of most of the cancers.

AB - The conventional definition for rare disease is based on prevalence. Because of differences in prognosis, a definition on the basis of incidence was deemed to be more appropriate for rare cancers. Within the European RARECARE project, a definition was introduced that defines cancers as rare when the crude incidence rate is less than six per 100 000 per year. In this study, we applied the RARECARE definition for rare cancer to the Netherlands; this to identify the usefulness of the definition in a single country and to provide more insight into the burden of rare cancers in the Netherlands. Data for 2004 through 2008 were extracted from the Netherlands Cancer Registry and classified according to the RARECARE entities (tumour groupings). Crude and European standardized incidence rates were calculated. Out of the 260 entities, 223 (86%) were rare according to the definition, accounting for 14 000 cancers (17% of all). Considerable fluctuations in crude rates over years were observed for the major group of cancers. Rare tumours in the Netherlands constituted 17% of all newly diagnosed tumours, but were divided over 223 different entities, indicating the challenge that faces clinicians. To make the definition of rare cancers better applicable, it should be refined by taking into consideration the sex-specific incidence for sex-specific cancer sites. Moreover, a mean incidence over 5 years will provide more solid insight into the burden, eliminating large fluctuations in time of most of the cancers.

KW - epidemiology

KW - incidence

KW - rare cancers

KW - the Netherlands

UR - http://www.scopus.com/inward/record.url?scp=85021974500&partnerID=8YFLogxK

U2 - 10.1097/CEJ.0000000000000166

DO - 10.1097/CEJ.0000000000000166

M3 - Article

AN - SCOPUS:85021974500

VL - 27

SP - 384

EP - 390

JO - European journal of cancer prevention

JF - European journal of cancer prevention

SN - 0959-8278

IS - 4

ER -

Van Der Zwan JM, Van Dijk BAC, Visser O, Van Krieken HJHJM, Capocaccia R, Siesling S. Rare cancers in the Netherlands: A population-based study. European journal of cancer prevention. 2018 Jan 1;27(4):384-390. https://doi.org/10.1097/CEJ.0000000000000166